Hester Biosciences Ltd. share price target

Revenue segment wise: poultry healthcare:73%, animal healthcare: 19%, others:8%; by geography: domestic:81%, exports:10%, others:9% Q3FY22 Results: Numbers were impacted by base effect....

Despite exports being impacted by air shipment restrictions due to Covid, Hester ended FY21 on a relatively strong note amid strong demand for poultry vaccines and health products in domestic market. Going ahead, opportunities panning out from animal vaccines such as classical swine fever, lumpy skin disease (only player) and sheep pox (only player) in the domestic space besides increased focus on health products, growth prospects look promising for Hester. Additionally, the management intends to move away from preventive healthcare to curative healthcare as a long...

After witnessing muted performances in the last few quarters, first on account of maize price issues affecting poultry vaccines and then the Covid related disturbances, the Q2 performance witnessed a substantial revival. Going ahead, opportunities panning out from PPR, Brucella vaccine tenders being floated in near term besides increased focus on health products, growth prospects looks promising for animal segment. That said, higher dependence on poultry segment and mostly tenderised nature of animal vaccine segment in the domestic market continue to influence...

The poultry vaccine business faced significant headwinds in FY20 as a sharp spike in maize prices (accounting for ~50% of feed cost) hampered the vaccination drive among poultry farmers. Just when things were returning to normalcy, came the Covid disturbance. Uncertainty remains upon normalisation of chicken, egg consumption pattern to pre-Covid level. The animal health segment, on the other hand, is expected to remain strong due to tenders and strong export potential. However, fortunes in the poultry segment would continue to weigh on sentiments. We arrive at a...

ICICI Securities Ltd | Retail Equity Research Standalone revenues grew 20% YoY in H1FY19 to | 80.8 crore on the back of 36% growth in the large animal segment to | 14.8 crore and addition of veterinary social business. The poultry segment grew 10% YoY in H1FY19 to | 62.3 crore EBITDA margins remained healthy at 38% in H1FY19. EBITDA grew 18% YoY in H1FY19 to | 30.5 crore Net profit grew 30% YoY to | 19.6 in H1FY19 crore mainly due to a...

Domestic Brucella and PPR Vaccines Sales Drive Profitability: A surprise and significant jump in domestic Large Animal Vaccines (LAV) sales - primarily Brucella vaccine and to smaller degree PPR vaccines - have led to considerableexpansion in gross margin and EBITDA margin.

Nepal Plant Commissioned: The PPR vaccines manufacturing facility in Nepal has started commercial operations and would be manufacturing PPR vaccines for exports primarily to African countries. Commissioning of plant was delayed because of which most of PPR sales are likely to occur in the year 2017E and thereafter. We believe that successful operations of this plant are expected to lead to manufacturing of safe and effective vaccines, and thus is a defining moment in the history of HesterBiosciences Ltd (HBL). PPR is a plague affecting Sheep and Goats.

Hester Biosciences Ltd. posted robust growth in 1QFY17 with revenue growth of 22.8%/6.9% YoY/QoQ, respectively, to Rs 301mn led by 21.6%/41% growth in poultry segment/Large animal segment. EBITDA for the quarter grew by 31%/9.8% YoY/QoQ respectively to Rs 107mn with the expansion in EBITDA margins by 222/94bps YoY/QoQ to 35.5% mainly due to shift in product mix, better inventory management, credit control and lower financing cost.

Steady performance captured in price; revised to Hold Hester Biosciences Ltd. posted robust growth in 4QFY16 with revenue growth of 21%/17% YoY/QoQ, respectively, to Rs 282mn led by 9%/96%...

Poultry vaccines to grow at ~16%: Poultry segment in India commands 2nd most important place after Livestock. India is third largest country in Egg production with 70 billion eggs and at fourth largest in broiler / chicken meat...

Buy Hester Biosciences Ltd in dips of Rs. 307 - Rs. 338